Investigating Apatorsen in Advanced Bladder Cancer in Combination with Second-Line Chemotherapy

Phase 2 Trial Borealis-2
Investigating Apatorsen in Advanced Bladder Cancer in Combination With Second-Line Chemotherapy

An investigator-sponsored, randomized Phase 2 trial evaluating apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy

About apatorsen and the ORCA Program

Apatorsen is a once-weekly intravenous (IV) drug designed to inhibit production of heat shock protein 27 (Hsp27) to disable cancer cells' defenses and overcome treatment resistance. Both the potential single-agent activity of apatorsen and its synergistic activity with cancer treatments may increase the overall benefit of existing therapies and augment the durability of treatment outcomes, which could lead to increased patient survival.

The ORCA™ (**O**ngoing Studies Evaluating Treatment **R**esistance in **CA**ncer) Program encompasses clinical studies of apatorsen aiming to demonstrate whether inhibition of Hsp27 can lead to improved prognoses and treatment outcomes for patients with cancer.

About the Borealis-2 Trial

Study population: Patients with advanced urothelial carcinoma (UC) who have disease progression following initial platinum-based chemotherapy treatment

Primary objective: To determine whether docetaxel administered in combination with apatorsen provides a survival benefit compared to docetaxel alone

Study design

- Patients in group 1 will receive 3 loading doses of apatorsen within a 9-day period followed by weekly IV infusions of apatorsen on Days 1, 8, and 15 of each 21-day cycle, plus docetaxel once every 21-day cycle
- Patients in group 2 will receive docetaxel once every 21-day cycle



Key inclusion criteria

- Age ≥18 years
- Histologically documented metastatic or inoperable, locally advanced UC
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria
- Received prior systemic chemotherapy treatment for metastatic or inoperable UC

  NOTE: Up to 2 systemic chemotherapeutic regimens given in the metastatic disease setting for UC are allowed. Specifically, subjects must meet 1 or more of the following criteria:
  - Progression during or after treatment with a regimen that includes a platinum agent, OR
  - Disease recurrence within 1 year after neoadjuvant or adjuvant platinum-based systemic chemotherapy, measured from the date of last dose of chemotherapy or surgery until the day the informed consent is signed
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
- Minimum of 21 days elapsed since prior major surgery or radiation therapy
- Adequate bone marrow, liver, and renal function

Key exclusion criteria

- History of treatment with docetaxel. Participants treated with prior paclitaxel are eligible
- Prior enrollment in the OncoGenex™ Phase 2 Borealis-1 Trial (OGX-427-02)
- Receiving other investigational agents
- Known brain or spinal cord metastases
- History of allergic reactions or severe hypersensitivity reactions to drugs formulated with polysorbate 80 or antisense oligonucleotides
- Peripheral neuropathy ≥grade 2

ORCA Ongoing Studies Evaluating Treatment Resistance in CAncer

For more information on the Borealis-2 Trial, please visit www.clinicaltrials.gov (Identifier: NCT01780545) or contact the Hoosier Oncology Group, the study sponsor.

For more information on apatorsen and the ORCA Program, please visit www.ORCAtrials.com
Apatorsen is not approved for commercial use and is only available for investigational use in approved clinical trials.

OncoGenex™